Cryosa is a medical device company developing breakthrough, minimally invasive therapies for obstructive sleep apnea that do not require implants or daily patient compliance. The company is advancing a device intended to treat the root cause of OSA and is currently conducting first-in-human clinical trials. Leadership includes founder and chief medical officer Dr. Donald Gonzales and president and CEO Mark Christopherson. The recent financing will fund continuation of first-in-human work and expansion into the next phase of safety and efficacy clinical trials. Cryosa is led by a team of entrepreneurs, engineers, and professionals from medical device startups and large med‑tech companies and is based in Minnesota’s Medical Alley. The company notes an estimated 24 million people in the U.S. and 425 million globally have moderate to severe OSA. Cryosa develops breakthrough, minimally invasive and permanent medical-device therapies aimed at treating obstructive sleep apnea by selectively reducing adipose tissue in the upper airway. The company has completed extensive pre-clinical testing evaluating safety and efficacy. Cryosa intends to use its latest financing to initiate first-in-human clinical trials. The team includes founder and CMO Dr. Donald Gonzales and president/CEO Mark Christopherson, both with prior exits and deep medical device experience. The company is based in Medical Alley, Minnesota and emphasizes an experienced mix of startup entrepreneurs and large med-tech engineers. OSA affects roughly 22 million Americans, and Cryosa positions its therapy as addressing a large unmet need versus more invasive surgical options.

Total raised

$30M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2021